ArticleFrontiers in genetics2026
Pan-cancer screening, bioinformatics analysis, and experimental validation identify TEX10 as a key biomarker driving OSCC progression.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: TEX10 is a nuclear protein involved in chromatin remodeling. Its pan-cancer diagnostic, prognostic, and immunotherapeutic value has not been systematically evaluated, and its role in oral squamous cell carcinoma (OSCC) remains unclear. Methods: We employed TCGA and GTEx data for pan-cancer analysis of TEX10's prognostic and immune associations, along with OSCC-specific clinical, diagnostic and survival correlations. Protein-protein interaction (PPI) network, GO/KEGG enrichment analysis and Results: TEX10 was upregulated in 15 cancer types and served as a prognostic biomarker for multiple cancers. It was associated with dysregulation of the tumor immune microenvironment and significantly enriched in pathways including cell cycle and DNA replication. In oral squamous cell carcinoma, high TEX10 expression positively correlated with advanced clinical stage, TNM stage, and smoking history, demonstrating high diagnostic accuracy and prognostic value. Conclusion: TEX10 plays an important role in cell cycle progression in OSCC, showing promise as a diagnostic and prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.